Earnings summaries and quarterly performance for Anika Therapeutics.
Executive leadership at Anika Therapeutics.
Cheryl R. Blanchard
Detailed
President and Chief Executive Officer
CEO
David B. Colleran
Detailed
Executive Vice President, General Counsel and Secretary
Ian W. McLeod
Detailed
Vice President, Chief Accounting Officer and Treasurer
Stephen D. Griffin
Detailed
Executive Vice President, Chief Financial Officer and Chief Operating Officer
Board of directors at Anika Therapeutics.
Research analysts who have asked questions during Anika Therapeutics earnings calls.
Michael Petusky
Barrington Research
5 questions for ANIK
Also covers: HAE, HSIC, LFCR +8 more
Anderson Schock
B. Riley Securities
3 questions for ANIK
Also covers: CLPT, ELMD, INFU +8 more
James Sidoti
Sidoti & Company
3 questions for ANIK
Also covers: ASRT, GAIA, GOCO +10 more
Jim Sidoti
Sidoti & Company, LLC
2 questions for ANIK
Also covers: GAIA, GOCO, INFU +4 more
Recent press releases and 8-K filings for ANIK.
Anika Reports Q3 2025 Financial Results and Pipeline Progress
ANIK
Earnings
Guidance Update
Share Buyback
- Anika reported Q3 2025 revenue of $27.8 million, a 6% decrease year-over-year, primarily due to a 20% decline in OEM revenue. However, Commercial Channel revenue grew 22% year-over-year.
- The company achieved $0.9 million in Adjusted EBITDA and generated $6.9 million in cash from operations during Q3 2025.
- Anika submitted the Hyalofast® PMA on October 31 and commenced a $15 million 10b5-1 share repurchase program.
- The company is maintaining its full-year 2025 and long-term revenue guidance.
Nov 5, 2025, 1:30 PM
Anika Reports Q3 2025 Results, Advances Product Pipelines, and Maintains Full-Year Guidance
ANIK
Earnings
Guidance Update
Product Launch
- Anika reported Q3 2025 total revenue of $27.8 million, a 6% decline compared to the same period last year, with commercial channel revenue growing 22% to $12 million and OEM channel revenue declining 20% to $15.8 million.
- The company achieved positive adjusted EBITDA of $900,000 and generated strong operating cash flow of $6.9 million in Q3 2025, ending the quarter with $58 million in cash and no debt.
- Significant progress was made on key product pipelines, including the submission of the third and final PMA module for Hyalofast to the FDA and advancing Cingal towards NDA submission with completed toxicity studies and initiated patient screening for a bioequivalent study.
- The Integrity Implant System continued its strong momentum, driving 25% year-over-year growth in regenerative solutions and performing approximately 500 procedures in Q3 2025, with the company on track to more than double Integrity procedures and revenue in 2025.
- Anika is maintaining its full-year 2025 guidance, expecting commercial channel revenue between $47 million and $49.5 million and OEM channel revenue between $62 million and $65 million, with adjusted EBITDA guidance of positive 3% to negative 3%. The company also commenced a second $15 million share repurchase.
Nov 5, 2025, 1:30 PM
Anika Therapeutics Reports Q3 2025 Financial Results, Files Final Hyalofast PMA, and Initiates Share Repurchase
ANIK
Earnings
Guidance Update
Share Buyback
- Anika Therapeutics reported Q3 2025 revenue from continuing operations of $27.8 million, a 6% decrease year-over-year, with Commercial Channel revenue up 22% and OEM Channel revenue down 20%.
- For Q3 2025, the company posted a loss from continuing operations of ($3.2) million, or ($0.22) per share, but an adjusted net income from continuing operations of $0.7 million, or $0.04 per share.
- The third and final PMA module for Hyalofast was filed with the FDA on October 31, 2025, although the pivotal FastTRACK Phase III study did not meet its pre-specified co-primary endpoints under the original statistical framework.
- Anika reaffirmed its Fiscal 2025 guidance and initiated a $15 million 10b5-1 share repurchase program, expected to conclude by June 2026.
- J&J MedTech extended its license and supply agreement for Monovisc for an additional 5-year term through December 2031, and Cingal surpassed one million injections worldwide since its 2016 launch.
Nov 5, 2025, 12:20 PM
Anika Therapeutics Announces Third Quarter 2025 Financial Results
ANIK
Earnings
Guidance Update
Share Buyback
- Anika Therapeutics reported third quarter 2025 revenue from continuing operations of $27.8 million, representing a 6% decrease compared to the same period in 2024, and a loss from continuing operations of ($3.2) million or ($0.22) per share.
- The company's Commercial Channel revenue increased 22% year over year, while OEM Channel revenue decreased 20%.
- Anika is reaffirming its Fiscal 2025 guidance, with Commercial Channel revenue expected to be $47 to $49.5 million (up 12% to 18%) and OEM Channel revenue $62 to $65 million (down 16% to 20%).
- The company is commencing a $15 million 10b5-1 share repurchase program, anticipated to be completed by June 2026.
- Key product developments include the filing of the third and final Hyalofast PMA module and data release, and Cingal achieving over one million injections worldwide since 2016.
Nov 5, 2025, 12:05 PM
Anika Therapeutics Files Final Hyalofast PMA Module and Reports Phase III Study Data
ANIK
Product Launch
New Projects/Investments
- Anika Therapeutics filed the third and final module of its Premarket Approval (PMA) application for Hyalofast with the U.S. Food and Drug Administration (FDA) on October 31, 2025.
- The U.S. pivotal Phase III FastTRACK clinical trial for Hyalofast did not meet its pre-specified co-primary endpoints under the original statistical framework.
- However, post-hoc analysis and key secondary endpoints demonstrated statistically significant improvements for Hyalofast in KOOS Pain, KOOS Sports and Recreation, KOOS Quality of Life, and Total KOOS.
- A responder analysis indicated a significantly greater proportion of Hyalofast patients achieved clinically meaningful improvements in KOOS Pain compared to microfracture patients.
- Anika remains confident in Hyalofast's clinical value, citing over 35,000 patients treated globally since 2009 and FDA Breakthrough Device Designation.
Nov 5, 2025, 12:00 PM
Anika Therapeutics Q1 2025 Earnings Overview & Call
ANIK
Earnings
Guidance Update
Share Buyback
Product Launch
- Revenue from continuing operations was $26.2M (-10% YoY): Commercial Channel grew 18% while OEM Channel declined 23%
- Integrity and regenerative solutions drove growth with over 300 surgeries in Q1 and a 33% YoY increase, while key regulatory and clinical milestones for Hyalofast and Cingal set the stage for upcoming NDA filings and U.S. launch activities
- Operating expenses declined 12% to $19.0M while maintaining a 56% gross margin amid a $4M sales drop and manufacturing yield issues
- Updated full-year guidance now projects Commercial Channel revenue of $47–$49.5M (approx. 12%-18% growth) and an OEM decline of 16%-20%, with revised Adjusted EBITDA of –3% to +3%
- Corporate actions included the sale of Parcus Medical, transition services for the Arthrosurface sale, and completion of a $15M share repurchase plan ahead of schedule
May 9, 2025, 12:31 PM
Anika Therapeutics Reports Q4 2024 Performance Results
ANIK
Earnings
Divestitures
Share Buyback
- Total Q4 revenue reached $30.6 million, up 1% YoY, with the commercial channel growing 25% to $10.9 million while the OEM channel declined 8%.
- The company completed the divestitures of Arthrosurface and Parcus Medical to sharpen its focus on core hyaluronic acid products.
- The Integrity product demonstrated robust momentum with over 40% sequential growth, recording more than 300 surgeries in Q4 and surpassing 1,000 procedures globally since launch.
- A $15 million share repurchase was completed ahead of schedule, and the company ended Q4 with $56 million in cash and no debt.
Mar 12, 2025, 9:01 PM
Anika Therapeutics Reports Q4 2024 Earnings Results
ANIK
Earnings
Revenue Acceleration/Inflection
Share Buyback
- Integrity Implant System delivered over 40% sequential growth for the third consecutive quarter, while the International OA Pain business maintained strong double-digit growth, reflecting improved commercial execution.
- Q4 2024 revenue reached $30.6M with Commercial revenue growing 25% to $10.9M, despite an 8% decline in OEM revenue, and gross profit recorded at $17.1M.
- The company increased R&D expenses due to the $600K Hyalofast FDA filing fee and executed a $15M share repurchase plan earlier than scheduled .
Mar 12, 2025, 9:00 PM
Anika Therapeutics Reports Q4 2024 Financial Results
ANIK
Earnings
Share Buyback
Revenue Acceleration/Inflection
- Q4 continuing operations revenue reached $30.6 million, reflecting a 1% year-over-year increase, with Commercial Channel revenue up 25% and OEM Channel revenue down 8%.
- Full-year 2024 revenue totaled $119.9 million, showing a 1% decline from 2023, while Commercial Channel revenue increased by 17% and OEM Channel revenue declined by 8%.
- Key milestones were achieved, including >40% sequential growth for the Integrity Implant System and significant regulatory/clinical progress for products like Hyalofast and Cingal.
- The company executed a share buyback program, purchasing $5.6 million in common stock, and ended the quarter with a strong cash balance of $55.6 million and no debt.
Mar 12, 2025, 12:00 AM
Recent SEC filings and earnings call transcripts for ANIK.
No recent filings or transcripts found for ANIK.